With LLS support, Dr. Druker pioneered targeted therapy, a cornerstone of precision medicine. His work led to the development of imatinib (Gleevec®), which revolutionized CML treatment and has saved 350,000 lives globally. Today, Dr. Druker is driving innovation in precision medicine through our Beat AML Master Clinical Trial.
Brian Druker, M.D.,
The Knight Cancer Institute at Oregon Health & Science University